The U.S. Food and Drug Administration approved Eli Lilly's Olumiant (baricitinib), a once-daily JAK inhibitor (immune-signaling medicine), for patients aged 12 and older with severe alopecia areata, a chronic immune-mediated disease that causes unpredictable hair loss. The expanded U.S. label is supported by 36-week results from BRAVE-AA-PEDS, the first and largest Phase 3 study specifically designed for pediatric patients with severe alopecia areata. Among adolescents with a median baseline SALT score of 100, indicating complete scalp hair loss, 42% receiving Olumiant 4 mg and 27% receiving 2 mg achieved at least 80% scalp hair coverage, compared with 5% on placebo. At least 90% scalp coverage was achieved by 37% of patients on 4 mg, 21% on 2 mg and 2% on placebo. The 4 mg group also showed improved eyebrow and eyelash coverage among patients with substantial hair loss in those areas. The approval expands Olumiant's existing U.S. uses in adults with severe alopecia areata and moderately to severely active rheumatoid arthritis. The product's U.S. labeling carries a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis.